XenoPort Investors' Horizant Suit Tossed For Now

Law360, New York (May 23, 2011, 12:52 PM EDT) -- A federal judge in California on Friday tossed a shareholder class action against XenoPort Inc., saying claims that the company withheld information about problems delaying the approval of restless legs syndrome drug Horizant weren't sufficient and needed to be redrawn.

After a hearing, U.S. District Judge Ronald M. Whyte ruled in favor of the Santa Clara, Calif.-based biopharmaceutical company and several of its top executives, but gave lead plaintiff Ie-Chen Cheng 30 days to replead her proposed class action.

The plaintiffs claim Xenoport failed to disclose...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

In re Xenoport, Inc. Securities Litigation


Case Number

5:10-cv-03301

Court

California Northern

Nature of Suit

Securities/Commodities

Judge

Ronald M. Whyte

Date Filed

July 28, 2010

Law Firms

Companies

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.